Swiss Biotech HemostOD Secures CHF 2 Million Innosuisse Grant to Advance Universal Platelet Technology

Swiss Health Valley biotech company HemostOD has been awarded a CHF 2 million competitive grant from Innosuisse, the Swiss Innovation Agency, to support key development milestones for its groundbreaking platelet manufacturing platform.

The non-dilutive funding will play a pivotal role in strengthening HemostOD’s financial position as it moves towards major value-inflection points, including progressing toward Investigational New Drug (IND) clearance and launching a pilot production line to demonstrate commercial-scale capabilities.

“Our proprietary platform has the potential to revolutionize blood supply by producing unlimited platelets with improved safety and lower cost,” said Faouzi Khechana, CEO of HemostOD. “This innovative approach to platelet delivery could address a major unmet medical need and transform patient care in transfusion medicine.”

HemostOD is developing technology that produces donor-free, off-the-shelf universal human platelets using immortalized hematopoietic stem cells in a scalable bioreactor system—offering a potential solution to global platelet shortages that affect millions of cancer, trauma, and surgical patients each year.

Innosuisse’s start-up funding is highly competitive, with only around 10% of applicants approved. The CHF 2 million award underscores both the scientific excellence of HemostOD’s work and its potential for significant clinical and societal impact.

This investment positions HemostOD to accelerate its path toward regulatory engagement and commercial readiness, bringing its novel platelet technology one step closer to patients in need.

Last October, the biotech startup announced a CHF 4,3 Million seed- extension investment.

➡️ Source: Press Release | 📸 HemostOD team, Faouzi Ghechana (CEO), Nicoletta Sorvillo (CSO) and Elodie Dahan (CTO), ©HemostOD